D-Wave Quantum: Two Trimmed Targets, a Securities Suit and a 94.31% Lab Score Point to November 10
Published on 11/06/2026 at 03:51 | Editorial boerse-global.de
D-Wave Quantum has spent the past week collecting headlines that pull in opposite directions. On the corporate side, a pair of analysts reaffirmed their buy ratings while hacking away at price targets, and a securities class action landed against the company and certain executives. On the scientific side, a preliminary lung-cancer study produced a striking accuracy figure. The stock, meanwhile, has been moving to a rhythm set by the wider market rather than by anything D-Wave itself disclosed.
The sell-off came from the sector, not the company
Shares fell 11% in a broad retreat that hit technology and AI names, with chip stocks bearing the brunt of the selling pressure, according to AP. Quantum computing peers Rigetti Computing and IonQ were dragged down alongside D-Wave. No fresh company announcement was cited as the trigger. The prior session had already brought a 13% decline as the tech-wide rout rolled on.
That distinction matters when weighing the analyst notes that followed. Both target cuts were framed around sector weakness rather than any deterioration specific to D-Wave's operations.
Wedbush keeps its buy, lowers its number
Matt Bryson of Wedbush reiterated his buy recommendation while trimming his price target to $30 from $37. The move came a day after Craig Ellis of B. Riley Securities reaffirmed his own buy rating and cut his target to $27 from $40, pointing to softness across quantum computing and AI. Two analysts, two intact recommendations, two lower bars to clear. The pattern suggests conviction in the technology has survived the drawdown, but that expectations are being recalibrated while D-Wave works to convert technical milestones into commercial traction.
Should investors sell immediately? Or is it worth buying D-Wave Quantum?
A lawsuit, and a deadline to lead it
Pomerantz disclosed on October 29 that a securities class action had been filed against D-Wave and certain executives. The complaint alleges misleading statements about the business and its revenue prospects. The claims are unproven. Investors seeking to serve as lead plaintiff have until December 15, 2026, to file their motions.
The research cuts both ways
Monday brought the week's most concrete operational datapoint: a preliminary study by researchers at Florida Atlantic University on lung-cancer prediction under limited data conditions. According to the company, the annealing-based method reached 94.31% accuracy in simulation and 91.90% on quantum hardware. D-Wave noted that the work drew on a dataset expanded with additional data, and that further research is needed to establish how well the results carry over to independent clinical data. Until that replication arrives, the finding belongs in the promising-but-unverified column.
A second application signal came from customer Shionogi, which took first place in the quality-of-life category at the Japanese NEDO quantum computing competition on October 28. The 40 million ¥ prize supports further drug-discovery research — another step from award-winning research toward durable application, which is the transition investors ultimately need to see.
November 10 is the scorecard
D-Wave will report third-quarter 2026 results before the market opens on November 10, 2026. That release is where the tension between laboratory wins and commercial proof gets resolved, one way or the other. For now, the research record argues for opportunity, the trimmed targets argue for discipline, and the pending litigation argues for patience.
Ad
D-Wave Quantum Stock: New Analysis - 6 November
Fresh D-Wave Quantum information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
